Metsera launches with $290 million to focus on next-gen obesity and metabolic meds
New York USA-based Metsera, a company accelerating the next generation of medicines for obesity and metabolic diseases, announced its launch today.
Founded by Population Health Partners and ARCH Venture Partners and led by former executives of The Medicines Company, Metsera is rapidly advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies designed with best-in-class profiles to address multiple targets and meet the future needs of a rapidly evolving weight loss treatment landscape.
Current obesity market leaders are Denmark’s Novo Nordisk (NOV: N), with its Wegovy (semaglutide), and US major Eli Lilly (NYSE: LLY), with Zepbound (tirzepatide), but the exceptionally fast-growing sector has attracted a large number of small and big pharmas into licensing and M&A deals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze